Next Article in Journal
Spray Dried Formulations for Inhalation—Meaningful Characterisation of Powder Properties
Previous Article in Journal
Stabilisation and Growth of Metastable Form II of Fluconazole in Amorphous Solid Dispersions
Previous Article in Special Issue
Effectiveness of a Pharmacogenetic Tool at Improving Treatment Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Clinical Studies
Open AccessReview

Pharmacogenomic Characterization in Bipolar Spectrum Disorders

1
Maria Paola Belloni Center for Personalized Medicine, Data Medica Group (Synlab Limited), 35131 Padova, Italy
2
Department of Pharmaceutical & Pharmacological Sciences, University of Padova, 35131 Padova, Italy
3
Bendessere™ Study Center, Solgar Italia Multinutrient S.p.A., 35131 Padova, Italy
*
Author to whom correspondence should be addressed.
Pharmaceutics 2020, 12(1), 13; https://doi.org/10.3390/pharmaceutics12010013
Received: 25 November 2019 / Revised: 14 December 2019 / Accepted: 19 December 2019 / Published: 21 December 2019
(This article belongs to the Special Issue Pharmacogenomics in Psychiatry)
The holistic approach of personalized medicine, merging clinical and molecular characteristics to tailor the diagnostic and therapeutic path to each individual, is steadily spreading in clinical practice. Psychiatric disorders represent one of the most difficult diagnostic challenges, given their frequent mixed nature and intrinsic variability, as in bipolar disorders and depression. Patients misdiagnosed as depressed are often initially prescribed serotonergic antidepressants, a treatment that can exacerbate a previously unrecognized bipolar condition. Thanks to the use of the patient’s genomic profile, it is possible to recognize such risk and at the same time characterize specific genetic assets specifically associated with bipolar spectrum disorder, as well as with the individual response to the various therapeutic options. This provides the basis for molecular diagnosis and the definition of pharmacogenomic profiles, thus guiding therapeutic choices and allowing a safer and more effective use of psychotropic drugs. Here, we report the pharmacogenomics state of the art in bipolar disorders and suggest an algorithm for therapeutic regimen choice. View Full-Text
Keywords: personalized medicine; bipolar disorder; antipsychotics; mood stabilizers; pharmacogenomics personalized medicine; bipolar disorder; antipsychotics; mood stabilizers; pharmacogenomics
Show Figures

Figure 1

MDPI and ACS Style

Fortinguerra, S.; Sorrenti, V.; Giusti, P.; Zusso, M.; Buriani, A. Pharmacogenomic Characterization in Bipolar Spectrum Disorders. Pharmaceutics 2020, 12, 13.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop